Across TCGA pan-cancer cohorts, VTRNA1-3 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated VTRNA1-3 data layer.
The strongest signal is observed in mesothelioma (MESO), where higher VTRNA1-3 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated VTRNA1-3 expression acts as an unfavorable survival marker, although some lineages such as KIRP and READ show a favorable association.
MESO, STAD, and KIRC are the cancer types where VTRNA1-3 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.